Millions in US use unapproved GLP-1s—and use them in unapproved ways
摘要
美国疾控中心基于2025年7至8月对8000多名成年人的调查数据估计，约一成美国成年人（约2700万人）在2025年使用过GLP-1药物。研究显示，近半数使用者（44%）的用药方式与处方不同，包括跳过剂量、延迟续药或使用较小剂量等。超过半数调整用药者表示原因涉及费用或可及性，其中年轻使用者的费用障碍更为突出。
GLP-1 medications are everywhere these days. The peptide-based drugs are both highly effective and wildly popular for diabetes, weight loss and a growing range of connected chronic health conditions, including cardiovascular disease and obstructive sleep apnea. But, amid the boom, the latest data suggests millions of Americans have turned to unapproved versions and are using the potent drugs in ways doctors never intended, raising questions about what that real-world use means for safety and efficacy.
In a study published this week, researchers at the Centers for Disease Control and Prevention broke down survey data of GLP-1 use collected between July and August of 2025. Based on responses from over 8,000 US adults, the researchers estimate that about one in 10 US adults (9.8 percent) used a glucagon-like peptide-1 receptor agonist, aka GLP-1 medication, in 2025. That's around 27 million adults. The study was published in the CDC's Morbidity and Mortality Weekly Report.
Among GLP-1 users, nearly half (44 percent) reported using their GLP-1 in a way that was different from how it was prescribed. Users skipped doses, delayed getting refills, and used smaller doses than prescribed, among other changes. More than half of the people modifying how they used the drug said the changes were because of cost or availability reasons. Cost and access barriers were most pronounced among younger GLP-1 users. Fifty-eight percent of adults 14–39 years old who modified their use cited cost as a barrier, compared with just 20 percent of adults 65 or older who said the same.
转载信息
评论 (0)
暂无评论，来留下第一条评论吧